en Medical Biotechnology Medical Biotechnology مقاله کامل Full Length/Original Article <strong>Background:</strong> Acute myelocytic leukemia (AML) is a clonal malignancy resulting from the accumulation of genetic abnormalities in the cells. Human baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), encodes survivin, is one of only a handful of genes that is differentially over-expressed in numerous malignant diseases including AML. <strong>Methods: </strong>The <em>BIRC5 </em>was silenced permanently in two AML cell lines, HL‑60 and KG-1, via the CRISPR/Cas9n system. After transfection of CRISPR constructs, genomic DNA was extracted and amplified to assess mutation detection. To evaluate <em>BIRC5</em> gene expression, quantitative real-time PCR was performed. Also, MTT cell viability and Annexin‑V/propidium iodide flowcytometric staining were performed, and the data were analyzed using the Kolmogorov-Smirnov, Levene&#39;s, and ANOVA tests. <strong>Results:</strong> The results indicated that Cas9n and its sgRNAs successfully triggered site-specific cleavage and mutation in the <em>BIRC5</em> gene locus. Moreover, suppression of <em>BIRC5</em> resulted in the reduction of cell viability, and induction of apoptosis and necrosis in HL60 and KG1 suggested that the permanent suppression of <em>BIRC5</em> remarkably dropped the gene expression and cells viability. <strong>Conclusion:</strong> This study reinforces the idea that <em>BIRC5</em> disruption via Cas9n:sgRNAs has favorable effects<br> on the AML clinical outcome. It thereby can be a promising candidate in a variety of leukemia treatments. Acute myelocytic leukemia (AML), CRISPR, Gene editing, Survivin 369 378 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-786&slc_lang=en&sid=1 Manizheh Narimani 0000-0002-7848-0986 No Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran Mohammadreza Sharifi 0000-0002-1538-9034 No Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Mohammad Saeed Hakhamaneshi 0000-0002-5481-1031 No Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran Daem Roshani 0000-0003-4746-1114 No Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran Mohammad Kazemi 0000-0002-6794-6891 No Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Seyed Hossein Hejazi 0000-0002-3733-1220 No Skin Diseases and Leishmaniasis Research Center, Department of Parasitology & Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Ali Jalili 0000-0002-1833-4928 Yes Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran